Vaginal estrogen
Vaginal estrogen products treat the vaginal dryness, painful intercourse, and urinary symptoms of menopause with minimal systemic estrogen absorption.
How it works
Vaginal estrogen addresses genitourinary syndrome of menopause (GSM) — the cluster of vaginal and urinary symptoms caused by local estrogen deficiency: dryness, thinning of vaginal walls, painful intercourse, urgency, recurrent urinary tract infections. Unlike systemic hormone therapy, vaginal estrogen is formulated for local action: the dose is low and absorption into the bloodstream is minimal, which is why it is often prescribed for people who cannot or prefer not to use systemic estrogen — including breast cancer survivors, in many cases. Available forms include tablets (Vagifem), rings (Estring), creams (Premarin Cream, Estrace Cream), and softgel inserts (Imvexxy).
Because systemic absorption is low, a progestogen is generally not required with vaginal estrogen alone, though this should be confirmed with a physician in specific clinical situations. GSM symptoms are progressive if untreated — tracking them over time shows both the condition's trajectory and the treatment's effect. Improvements in vaginal dryness and discomfort may take four to twelve weeks to become fully apparent, since tissue restoration is gradual.
How to track Vaginal estrogen
- Vaginal dryness or discomfort level — the primary symptom target for all vaginal estrogen products.
- Painful intercourse (dyspareunia) if applicable — tracking both frequency and severity gives your physician a clear signal of whether the tissue is responding.
- Urinary urgency, frequency, or recurrent UTIs — vaginal estrogen often improves these as the local tissue environment is restored.
- Application consistency and schedule — tracking whether you are using the product as prescribed (e.g., twice weekly after an initial daily loading period) is essential for evaluating response.
- Local tolerability — discharge, spotting, or irritation at the application site, especially in early weeks.
- Rate vaginal dryness and discomfort on a consistent scale (e.g., 0–10) from the first week, even before symptoms are expected to improve — tissue response to local estrogen is gradual, and a week-by-week log shows the trajectory clearly.
- Separate dyspareunia tracking from general dryness — they often improve on different timelines, and your physician needs to know which symptoms are lagging.
- Log urinary urgency or UTI episodes with dates — vaginal estrogen has documented benefits on urinary symptoms, and tracking them confirms whether you're getting that benefit.
- Note the exact formulation (tablet, ring, insert, cream) and whether you are in the initial loading phase or the maintenance phase — these phases have different application schedules and tracking expectations.
- If you are also on systemic HRT, track vaginal symptoms separately — they may persist even with adequate systemic estradiol and often require local treatment added on top.
Questions to ask your physician
- My vaginal dryness rating before starting was [X]. At [N] weeks on vaginal estrogen, my current rating is [Y]. Is that improvement rate on track, or is more time needed?
- I've been logging dyspareunia at [frequency and severity] — here is the pattern over [N] weeks. Is that trajectory consistent with expected tissue response?
- My urinary urgency log shows [X] episodes per week before starting vs. [Y] currently. Is the improvement in urinary symptoms consistent with the expected effect of vaginal estrogen?
- I'm also on systemic estradiol but still have persistent vaginal symptoms. Based on my log, does the pattern suggest the systemic dose is insufficient, or is the local treatment not yet working?